Separation Systems for Commercial Biotechnology Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Market Overview

The separation systems for the commercial biotechnology market studied were projected to grow with a CAGR of 4.7% over the forecast period. The major factor attributing to the growth of the market is the increasing advancement of cell separations and increasing demand for biopharmaceuticals. Opportunities in biopharmaceuticals have been increasing over the past decade, as a result of great effectiveness and the safety of these drugs. Biopharmaceuticals have also reduced the number of deaths caused due to cancer and HIV/AIDS in the past decade, which has led to an increase in the adoption of biopharmaceuticals in the global market. Pulmozyme, a recombinant enzyme, is used to treat patients of cystic fibrosis with free DNA in their lungs. Earlier, there was no treatment other than manually pounding the patient’s chest. However, with the help of Pulmozyme, the patient was allowed to dislodge the free DNA from the lungs, which is more effective and safe. Furthermore, increasing government and private funding of the biotechnology segment is further boosting the market growth. However, the high cost of the research and development and patent rights over the MACS technique constraints the market growth.

Scope of the Report

As per the scope of the report, Separation Systems are used for the purification and separation of biological products such as biopharmaceuticals, biochemicals and diagnostic reagents depending upon the electrostatic charge, density, diffusivity, shape, polarity, solubility, and volatility characteristics. The equipment used for the separation of biological material from complex mixture or solution includes chromatography, membrane or filters, and centrifuges. This report is segmented by Method Type, Application, and Geography.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Biopharmaceutical Segment is Dominating the Separation Systems for Commercial Biotechnology Market.

Increasing demand for personalized medicines and cell-based therapies coupled with a recent global shortage of vaccines are placing new demands on the segment, thus increasing the adoption of new technology-based systems for large-scale downstream bioprocessing. Pharmaceutical companies that have strong biopharmaceutical pipeline, is rendering the growth of these instruments for purification of biomolecules from debris during its large production. According to the report Biopharmaceutical benchmarks 2018, from 2014 – 2017, 155 biopharmaceutical products have been approved in the United States and/or European Union and globally, 2017 sales generated cumulatively by all biosimilar reference products reached USD 73.3 billion. Furthermore, the increasing funding by the government and major players on the research and development is propelling the segment growth.

To understand key trends, Download Sample Report